Maravai LifeSciences Holdings, Inc. MRVI
7.68 USD -0.02 (-0.26%)
At closeNov 12, 2026, 6:19 PM EST
7.68 0.00 0.00%
After hours · Nov 12, 6:19 PM ET
7.60 Day range 7.93
2.83 52-week range 9.00
- YTD
- +136.31%
- 1 year
- +136.31%
News
benzinga.com Keybanc Upgrades Maravai LifeSciences to Overweight, Announces $11 Price Target Keybanc analyst Paul Knight upgrades Maravai LifeSciences (NASDAQ:MRVI) from Sector Weight to Overweight and announces $11 price target.
seekingalpha.com Maravai LifeSciences Holdings, Inc. (MRVI) Q3 2026 Earnings Call Transcript Maravai LifeSciences Holdings, Inc. ( MRVI ) Q3 2026 Earnings Call November 4, 2026 5:00 PM EST Company Participants Debra Hart - Senior Director of Investor Relations Bernd Brust - CEO & Director…
marketbeat.com What Maravai LifeSciences (MRVI) Said on Its Q3 Earnings Call Maravai LifeSciences NASDAQ: MRVI raised its 2026 revenue and adjusted EBITDA forecasts after reporting third-quarter sales growth of 10%, driven by demand for mRNA products and continued growth at…
zacks.com Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q3 Loss, Beats Revenue Estimates Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year…
benzinga.com Maravai LifeSciences Q3 2026 Earnings Call Transcript Maravai LifeSciences (NASDAQ:MRVI) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Maravai LifeSciences Raises FY2026 Sales Guidance from $205.000M-$215.000M to $212.000M-$216.000M vs $211.767M Est Maravai LifeSciences (NASDAQ:MRVI) raises FY2026 sales outlook from $205.000 million-$215.000 million to $212.000 million-$216.000 million vs $211.767 million estimate.
benzinga.com Maravai LifeSciences Q3 Adj. EPS $(0.03) Beats $(0.06) Estimate, Sales $45.851M Beat $43.566M Estimate Maravai LifeSciences (NASDAQ:MRVI) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 62.5 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Revolution Medicines (NASDAQ:RVMD) stock rose 14.1% to $227.83 during Wednesday's after-market session. The market value of their outstanding shares is at $41.6 billion. As per the news, the…
businesswire.com Maravai LifeSciences Reports Third Quarter 2026 Financial Results SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported…
businesswire.com Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026 SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its…
benzinga.com Full Transcript: Maravai LifeSciences Q2 2026 Earnings Call Maravai LifeSciences (NASDAQ:MRVI) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is…
defenseworld.net Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stock Has Average Price Target of $6.83 Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) has received an average recommendation of "Hold" from the five ratings firms that are covering the stock, Marketbeat reports. One…
businesswire.com TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has…
benzinga.com UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8 UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.
seekingalpha.com Maravai LifeSciences: The Post-COVID Reset Has Created An RNA Consumables Flywheel Maravai (MRVI) is evolving into an integrated supplier for the in vitro transcription (IVT) RNA workflow, embedding products across the customer lifecycle. Q2 2026 marked a profitability inflection,…
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Indaptus Therapeutics (NASDAQ:INDP) shares moved upwards by 34.0% to $1.26 during Thursday's regular session. The company's market cap stands at $125.2 million. BioVie (NASDAQ:BIVI) stock…
benzinga.com Deere, Coinbase Global, Nordson And Other Big Stocks Moving Higher On Wednesday Dow Jones down 300 points, Deere & Co shares up 7.9% after beating earnings expectations. SCTX, SCSC, BTBT, MRVI, HIVE, AHG, TEM, MARA, LB also gain.
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
defenseworld.net Dimensional Fund Advisors LP Boosts Holdings in Maravai LifeSciences Holdings, Inc. $MRVI Dimensional Fund Advisors LP boosted its holdings in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) by 64.8% in the undefined quarter, according to its most recent Form 13F filing with…
defenseworld.net Maravai LifeSciences (NASDAQ:MRVI) Shares Gap Down – Here’s Why Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI - Get Free Report) shares gapped down before the market opened on Friday. The stock had previously closed at $6.25, but opened at $5.60. Maravai…
benzinga.com Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $6.5 Wells Fargo analyst Evan Stampler maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $5.5 to $6.5.
seekingalpha.com Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript Maravai LifeSciences Holdings, Inc. (MRVI) Q2 2026 Earnings Call Transcript
defenseworld.net Maravai LifeSciences Q2 Earnings Call Highlights Maravai LifeSciences (NASDAQ: MRVI) reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its…
marketbeat.com Maravai LifeSciences Q2 Earnings Call Highlights Maravai LifeSciences NASDAQ: MRVI reported second-quarter 2026 revenue growth and a sharp improvement in adjusted profitability, while maintaining its full-year revenue outlook and raising its…
zacks.com Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q2 Loss, Beats Revenue Estimates Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to a loss of $0.08 per share a year…- benzinga.com Maravai LifeSciences Affirms FY2026 Sales Guidance of $205.000M-$215.000M vs $210.433M Est Maravai LifeSciences (NASDAQ:MRVI) affirms FY2026 sales outlook from $205.000 million-$215.000 million to $205.000 million-$215.000 million vs $210.433 million estimate.
businesswire.com Maravai LifeSciences Reports Second Quarter 2026 Financial Results SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported…
businesswire.com Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026 SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its…- benzinga.com Maravai LifeSciences' TriLink BioTechnologies Obtains New Patent From The China National Intellectual Property Administration, Patent Number ZL 2025 1 1246578.X TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ:MRVI) and global provider of life science reagents and services, has been granted a new patent from the China National…
businesswire.com TriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping Technology SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has been granted a new…
gurufocus.com TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale TriLink, part of Maravai LifeSciences (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to h
businesswire.com TriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scale JUPITER, Fla.--(BUSINESS WIRE)--TriLink, part of Maravai LifeSciences® (NASDAQ: MRVI), today announced the opening of its GMP enzyme manufacturing facility in Jupiter, Florida, designed to help RNA…
businesswire.com Maravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032 SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Wells Fargo Maintains Overweight on Maravai LifeSciences, Raises Price Target to $5.5 Wells Fargo analyst Brandon Couillard maintains Maravai LifeSciences (NASDAQ:MRVI) with a Overweight and raises the price target from $4.5 to $5.5.
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Maravai LifeSciences Raises FY2026 Sales Guidance from $200.000M-$210.000M to $205.000M-$215.000M vs $204.933M Est Maravai LifeSciences (NASDAQ:MRVI) raises FY2026 sales outlook from $200.000 million-$210.000 million to $205.000 million-$215.000 million vs $204.933 million estimate.
- benzinga.com Maravai LifeSciences Q1 Adj. EPS $0.01 Beats $(0.05) Estimate, Sales $65.837M Beat $53.046M Estimate Maravai LifeSciences (NASDAQ:MRVI) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.05) by 120 percent. This is a 112.5 percent increase over losses of…
benzinga.com Earnings Scheduled For February 25, 2026 
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com Earnings Scheduled For August 11, 2025 
benzinga.com Earnings Scheduled For May 12, 2025 
benzinga.com Trump Media & Technology Group, BitFuFu, Mobileye Global And Other Big Stocks Moving Higher On Tuesday 
benzinga.com Earnings Scheduled For February 25, 2025 
benzinga.com Crude Oil Surges 3%; Delta Air Lines Posts Better-Than-Expected Earnings - benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Why Bank of Montreal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session.